[Prevention of thromboembolism with low molecular weight heparin (Fragmin) in obstetrics]
- PMID: 7975797
[Prevention of thromboembolism with low molecular weight heparin (Fragmin) in obstetrics]
Abstract
A total of 130 obstetrical patients were treated with either low molecular weight (LMW) or unfractionated (UFH) heparin as part of prospective study comparing their efficacy in the prevention of thromboembolism. A single daily dose of 2500-5000 anti-Xa-units LMW heparin (Fragmin) or two to three daily doses of 5000 IU UFH (Liquemin) were given to two groups of 15 patients with therapeutic tocolysis and 50 patients with cesarean section. Patients with cesarean section were given 500 ml Dextran 60 i.v. during surgery followed by subcutaneous injection of heparin eight to ten hours after surgery. Heparin therapy was continued for ten days after surgery. None of the patients exhibited clinical signs of thrombosis. The majority of patients showed symptoms of local irritation at the site of heparin injection (69% of patients with LMW heparin; 80% of patients with UFH). Hematomas at the site of injection were significantly smaller when LMW heparin was used instead of UFH. A number of patients experienced headache after heparin application (10% of patients with LMW heparin; 13% of patients with UFH). There were no cases of post surgical haemorrhage. Comparison of daily profiles revealed a significantly higher anti-Xa-activity of LMW heparin compared to UFH. In contrast, other coagulation parameters were not different in the two experimental groups (antithrombin III, partial thrombin time, thrombin time). Hematologic parameters and liver enzymes were in the physiological range in both experimental groups and none of the patients exhibited signs of heparin induced thrombocytopenia.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.Thromb Haemost. 2000 Apr;83(4):523-9. Thromb Haemost. 2000. PMID: 10780310 Clinical Trial.
-
[Prevention of thromboembolism in hysterectomies with low molecular weight heparin Fragmin].Geburtshilfe Frauenheilkd. 1988 Mar;48(3):160-4. doi: 10.1055/s-2008-1035716. Geburtshilfe Frauenheilkd. 1988. PMID: 2836259 Clinical Trial. German.
-
Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis.Semin Thromb Hemost. 1997;23(1):83-90. doi: 10.1055/s-2007-996074. Semin Thromb Hemost. 1997. PMID: 9156415 Clinical Trial.
-
[Pharmacologic and clinical principles for rational anti-thrombotic preventive treatment with low molecular weight heparin].Langenbecks Arch Chir Suppl II Verh Dtsch Ges Chir. 1990:1149-55. Langenbecks Arch Chir Suppl II Verh Dtsch Ges Chir. 1990. PMID: 1983502 Review. German.
-
[Prevention of thrombosis with unfractionated and low molecular weight heparin].Wien Med Wochenschr. 1989 Dec 15;139(23):555-9. Wien Med Wochenschr. 1989. PMID: 2560285 Review. German.
Cited by
-
[Heparin-induced thrombocytopenia with unfractionated heparin. A prospective study of inpatient treatment of internal medicine patients].Med Klin (Munich). 1998 Jun 15;93(6):343-6. doi: 10.1007/BF03044677. Med Klin (Munich). 1998. PMID: 9662940 German.
-
Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period.Cochrane Database Syst Rev. 2010 May 12;(5):CD001689. doi: 10.1002/14651858.CD001689.pub2. Cochrane Database Syst Rev. 2010. Update in: Cochrane Database Syst Rev. 2014 Feb 11;(2):CD001689. doi: 10.1002/14651858.CD001689.pub3. PMID: 20464719 Free PMC article. Updated.
-
Venous thromboembolism prophylaxis for women at risk during pregnancy and the early postnatal period.Cochrane Database Syst Rev. 2021 Mar 29;3(3):CD001689. doi: 10.1002/14651858.CD001689.pub4. Cochrane Database Syst Rev. 2021. PMID: 33779986 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical